Aytu BioPharma 2026 Q1 Earnings Record Net Income Growth of 33.3%

Aytu BioPharma reported fiscal 2026 Q1 earnings on Nov 13, 2025, with a 16.2% revenue decline to $13.89 million but a 33.3% surge in net income to $1.97 million. The company confirmed EXXUA’s Q4 2025 launch and projected adjusted EBITDA positivity in Q1 2026, excluding EXXUA launch costs.

Revenue

Aytu BioPharma’s total revenue fell 16.2% year-over-year to $13.89 million in Q1 2026, compared to $16.57 million in Q1 2025. The decline was attributed to a one-time $3.3 million rebate in the prior year’s ADHD Portfolio. Excluding this, the ADHD segment would have shown a 5% year-over-year revenue increase.

Earnings/Net Income

The company’s EPS dipped 12.5% to $0.21 in Q1 2026 from $0.24 in Q1 2025. However, net income surged to $1.97 million, a 33.3% increase from $1.47 million, marking a record high for fiscal Q1 net income in 11 years. Despite the EPS decline, the significant net income growth indicates strong cost management and operational efficiency.

Price Action

Aytu BioPharma’s stock edged up 0.49% during the latest trading day but dropped 3.74% in the most recent full week and 13.45% month-to-date.

Post-Earnings Price Action Review

Post-earnings, the stock’s performance reflected mixed sentiment. While the record net income and EXXUA launch plans provided some optimism, the revenue decline and EPS miss weighed on investor confidence. The 13.45% monthly drop suggests ongoing pressure from market concerns about the Pediatric Portfolio’s manufacturing delays and broader market volatility.

CEO Commentary

CEO Josh Disbrow highlighted EXXUA as the company’s core growth driver, with commercialization on track for Q4 2025. He noted stability in the ADHD Portfolio (10% growth excluding the 2025 rebate) and emphasized the Aytu RxConnect® platform’s role in patient access. Challenges in the Pediatric Portfolio due to supplier issues were acknowledged, but Disbrow expressed confidence in overcoming them.

Guidance

Aytu confirmed EXXUA’s December 2025 launch, with manufacturing and logistics finalized. The ADHD Portfolio is expected to remain stable, while the Pediatric Portfolio faces temporary disruptions. Adjusted EBITDA is projected to turn positive in Q1 2026, excluding EXXUA launch investments. The company anticipates $32.6 million in cash and equivalents to support these initiatives.

Additional News

Aytu BioPharma recently extended EXXUA’s method of use patent through September 2030, bolstering long-term intellectual property protection. The company also announced plans to publish new peer-reviewed research on EXXUA, aiming to strengthen its scientific credibility. Additionally, Aytu reiterated its commitment to refining sales territory strategies and integrating EXXUA into its patient support platform, Aytu RxConnect®.

Key Non-Earnings News Highlights:

1. EXXUA Patent Extension:

   Aytu extended EXXUA’s method of use patent to 2030, enhancing market exclusivity.

2. ADHD Portfolio Stability:

   The ADHD segment is projected to remain stable, driven by the Aytu RxConnect® platform and a new authorized generic.

3. Pediatric Portfolio Challenges:

   Manufacturing delays in the Pediatric Portfolio were acknowledged, though the company emphasized its commitment to resolving supplier issues.

Aytu BioPharma’s strategic focus on EXXUA’s commercialization and operational efficiency positions it to capitalize on the $22B MDD market, despite near-term challenges in its existing portfolios.